Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Penson · SciRah

Researcher profile · Semantic Scholar

R. Penson

Share profile

R. Penson — researcher profile on SciRah

h-index: 66
Works: 339
Citations: 18K

Most-cited papers

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
P. Konstantinopoulos, S. Waggoner, G. Vidal, M. Mita +21 more
2019JAMA Oncology515 citations Open access
Semantic Scholar
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
A. Poveda, A. Floquet, J. Ledermann, R. Asher +18 more
2021The Lancet Oncology363 citations Open access
Semantic Scholar
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
D. Armstrong, R. Alvarez, J. Bakkum-Gamez, L. Barroilhet +28 more
2019The Journal of the National Comprehensive Cancer Network248 citations Open access
Semantic Scholar
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
R. Penson, R. Valencia, D. Cibula, N. Colombo +12 more
2020Journal of Clinical Oncology229 citations Open access
Semantic Scholar
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Joyce F. Liu, C. Herold, K. Gray, R. Penson +9 more
2019JAMA Oncology210 citations Open access
Semantic Scholar
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer.
P. Konstantinopoulos, W. Luo, Joyce F. Liu, D. Gulhan +20 more
2019Journal of Clinical Oncology191 citations Open access
Semantic Scholar
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
Panagiotis A. Konstantinopoulos, Su-Chun Cheng, A. Wahner Hendrickson, R. Penson +20 more
2020The Lancet Oncology186 citations Open access
Semantic Scholar
TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.
P. Konstantinopoulos, S. Waggoner, G. Vidal, M. Mita +16 more
2018131 citations
Semantic Scholar
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
D. O'Malley, U. Matulonis, M. Birrer, Cesar M. Castro +9 more
2020Gynecologic Oncology127 citations
Semantic Scholar
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial
M. Friedlander, V. Gebski, E. Gibbs, L. Davies +18 more
2018The Lancet Oncology122 citations Open access
Semantic Scholar
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.
A. Poveda, A. Floquet, J. Ledermann, R. Asher +15 more
202098 citations
Semantic Scholar
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor
M. Gore, A. Hackshaw, W. Brady, R. Penson +18 more
2019Gynecologic Oncology86 citations Open access
Semantic Scholar
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Elizabeth K. Lee, N. Xiong, Su-Chun Cheng, W. Barry +14 more
2020Gynecologic Oncology85 citations
Semantic Scholar
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Y. Drew, Jae-Weon Kim, R. Penson, D. O'Malley +23 more
2023Clinical Cancer Research76 citations Open access
Semantic Scholar
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor–Positive Recurrent Endometrial Cancer
P. Konstantinopoulos, Elizabeth K. Lee, N. Xiong, C. Krasner +17 more
2022Journal of Clinical Oncology76 citations
Semantic Scholar
Second-line lenvatinib in patients with recurrent endometrial cancer.
I. Vergote, M. Powell, M. Teneriello, D. Miller +9 more
2020Gynecologic Oncology68 citations Open access
Semantic Scholar
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
Y. Drew, R. Penson, D. O'Malley, J. Y. Kim +15 more
202060 citations Open access
Semantic Scholar
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
B. You, G. Freyer, A. González-Martín, S. Lheureux +4 more
2021Cancer Treatment Reviews51 citations Open access
Semantic Scholar
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
P. Konstantinopoulos, A. Gockley, N. Xiong, C. Krasner +20 more
2022JAMA Oncology50 citations Open access
Semantic Scholar
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
C. Krasner, S. Campos, Chantay L. Young, Karan R. Chadda +7 more
2021Gynecologic Oncology38 citations
Semantic Scholar
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
S. Pignata, M. Bookman, J. Sehouli, A. Miller +21 more
2023Gynecologic Oncology31 citations
Semantic Scholar
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
W. Mcguire, R. Penson, M. Gore, A. Herráez +3 more
2018BMC Cancer30 citations Open access
Semantic Scholar
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
Nicholas Hirschl, Wildnese Leveque, Julia Granitto, Valia R. Sammarco +2 more
2024Cancers26 citations Open access
Semantic Scholar
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology – Gynecologic Oncology Group Study 240 (NCT 00803062)
K. Tewari, M. Sill, B. Monk, R. Penson +17 more
2020Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
R. Penson, Ricardo Villalobos Valencia, D. Cibula, N. Colombo +12 more
2019Journal of Clinical Oncology26 citations
Semantic Scholar
726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
N. Colombo, D. Lorusso, A. Herráez, A. Santin +16 more
2021Annals of Oncology25 citations Open access
Semantic Scholar
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
R. Corcoran, K. Do, J. E. Kim, J. Cleary +27 more
2024Clinical Cancer Research24 citations Open access
Semantic Scholar
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
F. Trillsch, S. Mahner, B. Ataseven, R. Asher +17 more
2022Gynecologic Oncology22 citations Open access
Semantic Scholar
A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.
H. Burris, A. Spira, M. Taylor, O. Yeku +14 more
202122 citations
Semantic Scholar
813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO2/ENGOT Ov-21 trial
J. Frenel, J. Y. Kim, D. Berton-Rigaud, R. Asher +15 more
202022 citations Open access
Semantic Scholar
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
P. Konstantinopoulos, Su-Chun Cheng, Elizabeth K. Lee, A. D. da Costa +16 more
2024JCO Precision Oncology21 citations Open access
Semantic Scholar
A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer.
Joyce F. Liu, C. Herold, W. Luo, R. Penson +7 more
2018Annals of Oncology21 citations Open access
Semantic Scholar
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
R. Arend, H. Beer, Y. Cohen, S. Berlin +7 more
2020Gynecologic Oncology20 citations Open access
Semantic Scholar
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
A. Tjokrowidjaja, C. Lee, M. Friedlander, V. Gebski +19 more
2020European Journal of Cancer19 citations Open access
Semantic Scholar
A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC).
K. Cadoo, M. Meyers, R. Burger, D. Armstrong +12 more
2019Journal of Clinical Oncology19 citations
Semantic Scholar
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
K. Tewari, M. Sill, M. Birrer, R. Penson +9 more
2023Gynecologic Oncology17 citations Open access
Semantic Scholar
CD90low MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer
Yang Zeng, Bing-Hao Li, Tao Li, Wei Liu +5 more
2019OncoTarget16 citations Open access
Semantic Scholar
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
R. Arend, Bradley J. Monk, R. Shapira-Frommer, Ashley F. Haggerty +87 more
2023Journal of Clinical Oncology15 citations Open access
Semantic Scholar
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
N. Lukashchuk, J. Armenia, L. Tobalina, T. Carr +5 more
2022Journal of Clinical Oncology15 citations
Semantic Scholar
A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Joyce F. Liu, W. Barry, R. Wenham, A. Wahner Hendrickson +16 more
201814 citations
Semantic Scholar
Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer.
Timothy P Lax, D. Dizon, M. Birrer, A. Long +7 more
2017Journal of Allergy and Clinical Immunology: In Practice13 citations
Semantic Scholar
MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours - new ovarian cancer cohorts.
R. Penson, Y. Drew, M. D. de Jonge, S. Hong +13 more
2018Annals of Oncology12 citations Open access
Semantic Scholar
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results
G. Scambia, Ricardo Villalobos Valencia, N. Colombo, D. Cibula +13 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).
R. Naumann, F. Braiteh, Lainie P. Martin, E. Hamilton +14 more
202111 citations
Semantic Scholar
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
R. Arend, B. Monk, T. Herzog, K. Moore +10 more
2021Gynecologic Oncology11 citations Open access
Semantic Scholar
Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer
R. Nitecki, Alexandra S. Bercow, A. Gockley, Hang Lee +2 more
2020International Journal of Gynecological Cancer11 citations Open access
Semantic Scholar
Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
J. Ledermann, A. Lortholary, R. Penson, E. Gibbs +16 more
201711 citations
Semantic Scholar
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
P. Konstantinopoulos, Ningxuan Zhou, R. Penson, T. Le +19 more
2025Nature Communications10 citations Open access
Semantic Scholar
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer.
V. Makker, Antonio Casado Herráez, C. Aghajanian, K. Fujiwara +8 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer
U. Matulonis, W. Barry, R. Penson, P. Konstantinopoulos +10 more
2018Gynecologic Oncology10 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

U. Matulonis×13
Invite
U. Matulonis — researcher profile on SciRah
P. Konstantinopoulos×10
Invite
P. Konstantinopoulos — researcher profile on SciRah
Joyce F. Liu×9
Invite
Joyce F. Liu — researcher profile on SciRah
E. Pujade-Lauraine×8
Invite
E. Pujade-Lauraine — researcher profile on SciRah

×8

Invite

N. Colombo — researcher profile on SciRah

J. Ledermann×7

Invite

J. Ledermann — researcher profile on SciRah

Invite

T. Huzarski — researcher profile on SciRah

Invite

C. Krasner — researcher profile on SciRah

Invite

S. Campos — researcher profile on SciRah

Invite

S. Pignata — researcher profile on SciRah

Invite

G. Sonke — researcher profile on SciRah

Invite

N. Horowitz — researcher profile on SciRah